BC Week In Review | Jul 25, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial final data

Final data from 320 inadequately controlled obese patients with Type II diabetes in the modified intent-to-treat (mITT) population of the double-blind, U.S. pivotal ENDO trial showed that EndoBarrier Gastrointestinal Liner reduced mean HbA1c from baseline...
BC Week In Review | Mar 21, 2016
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial data

Top-line data from the double-blind, U.S. pivotal ENDO trial in 325 inadequately controlled obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner missed the co-primary endpoint of reducing mean HbA1c from baseline to...
BC Week In Review | Sep 28, 2015
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial discontinued

GI Dynamics discontinued the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner following discussions with FDA regarding the trial’s possible resumption. In March, FDA placed a clinical hold on enrollment in the trial...
BC Week In Review | Apr 13, 2015
Clinical News

EndoBarrier: Pivotal trial hold

Last month, FDA placed a clinical hold on enrollment in the double-blind, sham-controlled, U.S. pivotal ENDO trial of EndoBarrier Gastrointestinal Liner due to 4 cases of hepatic abscess among the 325 obese Type II diabetics...
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)....
BC Extra | Jul 3, 2013
Financial News

GI Dynamics raises A$38.1 million

GI Dynamics Inc. (ASX:GID) raised A$38.1 million ($35 million) through the sale of 71.8 million CHESS Depository Interests (CDIs) at A$0.53 in a private placement. Each CDI represents a fifth of a common share. GI...
BC Week In Review | Jan 21, 2013
Company News

GI Dynamics, W.L. Gore & Associates gastrointestinal news

GI Dynamics and Gore settled litigation brought by Gore against GI Dynamics in 2010 in the U.S. District Court for the District of Arizona. The suit alleged that Gore was the co-owner of all of...
BC Week In Review | Jan 21, 2013
Clinical News

EndoBarrier Gastrointestinal Liner: Pivotal trial started

GI Dynamics began the double-blind, sham-controlled, U.S. pivotal ENDO trial to evaluate the EndoBarrier Gastrointestinal Liner in about 500 obese Type II diabetics. The product is marketed in Australia, Chile, Germany, Austria, the U.K. and...
BC Week In Review | Apr 23, 2012
Company News

GI Dynamics sales and marketing update

GI Dynamics launched EndoBarrier in Australia to treat obesity and Type II diabetes. The non-surgical liner endoscopically placed in the GI tract to create a barrier between food and the wall of the intestine is...
BC Week In Review | Jan 9, 2012
Company News

GI Dynamics sales and marketing update

GI Dynamics launched EndoBarrier Gastrointestinal Liner in the Netherlands to treat obesity and Type II diabetes. The non-surgical liner endoscopically placed in the GI tract to create a barrier between food and the wall of...
Items per page:
1 - 10 of 24